Source: globenewswire_biotech
Source ID: globenewswire_biotech:https://www.globenewswire.com/news-release/2026/11/04/3395231/0/en/sutro-biopharma-to-participate-in-upcoming-investor-conferences.html:STRO
URL: https://www.globenewswire.com/news-release/2026/11/04/3395231/0/en/sutro-biopharma-to-participate-in-upcoming-investor-conferences.html
Symbol: (STRO)
Published: 2026-11-04 08:00:00 EST
Time precision: minute
Title: Sutro Biopharma to Participate in Upcoming Investor Conferences

Accessibility: Skip TopNav
Sutro Biopharma to Participate in Upcoming Investor Conferences
November 04, 2026 08:00 ET
| Source:
Sutro Biopharma, Inc.
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.
Details of the Company’s participation are as follows:
Stifel Healthcare Conference
Fireside Chat Date/Time:
November 11 at 8:00 AM EST
Location:
New York, NY
Truist Securities Biopharma Symposium
Date:
November 12
Location:
New York, NY
UBS Global Biopharma Conference
Fireside Chat Date/Time:
November 17 at 10:40 AM GMT
Location:
London, UK
Jefferies Global Healthcare Conference
Fireside Chat Date/Time:
November 18 at 1:30 PM GMT
Location:
London, UK
Piper Sandler 38th Annual Healthcare Conference
Fireside Chat Date/Time:
December 2 at 1:30 PM EST
Location:
New York, NY
Where available, live webcasts of the presentations can be accessed on the Events & Presentations page in the Investor Relations section of the Company’s website at
www.sutrobio.com
. Archived replays will remain available for at least 30 days following each event.
About Sutro Biopharma
Sutro Biopharma, Inc. is a clinical-stage biotechnology company advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
For more information, follow Sutro on social media @Sutrobio or visit
www.sutrobio.com
.
Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com
Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
GlobeNewswire
Recommended Reading
October 21, 2026 08:00 ET
|
Source:
Sutro Biopharma, Inc.
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year — — Initial clinical data expected in the second half of 2027 — SOUTH SAN FRANCISCO, Calif., Oct. 21,...
Read More
October 12, 2026 08:00 ET
|
Source:
Sutro Biopharma, Inc.
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Read More
Explore
November 04, 2026 08:30 ET
Abercrombie & Fitch and Dallas Cowboys Wide Receiver CeeDee Lamb Launch Co-Designed Collection
November 04, 2026 08:30 ET
Eliminating Static Without Electricity - MEC Industries Introduces the Powerless ECO Ionizer
November 04, 2026 08:30 ET
“Building Armenia’s Next Phase of Growth”: the first FT Live forum in Armenia, in partnership with Wilco Wealth Management
November 04, 2026 08:28 ET
Directive Launches Commerce Division to Bring Specialized Performance Marketing to Underserved B2B Product Brands
November 04, 2026 08:11 ET
TAILG Showcases Long-Range Technology and a Versatile Product Lineup at EICMA 2026
❮
❯